- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03416582
Feasibility Study of a Nurse Intervention to Impact Mucositis Severity and Prevent Dehydration
Feasibility Study of a Nurse-Delivered Telephone Intervention To Impact Mucositis Symptom Severity and Prevent Dehydration in Lung and Head/Neck Cancer Patients Undergoing Chemoradiation: A Pilot Study
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33136
- University of Miami Sylvester Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Non-Small Cell or Limited Stage Small Cell Lung Cancer OR Head & Neck Cancer
- Over 18 years old
- Eligible for concurrent Chemoradiation in the first line setting
- Eastern Cooperative Group 0-2 (able to complete Activity of Daily Living (ADLs) independently or with assistive device only)
- Able to read & write English or Spanish
Exclusion Criteria:
- Under 18 years old
- Underlying Anxiety or Depression (must pass screening tools)
- Medically Diagnosed with a Cognitive Impairment
- No prior Chemotherapy or Radiation treatment
- No access to a telephone
- Blind or Deaf or Illiterate
- Requires assistance with Self-Care ADLs
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: SMENC Group
The Symptom Management Education and Nurse Coaching (SMENC) intervention is a one hour in-person face-to-face education session followed by twice weekly telephone calls conducted all throughout the patient's chemoradiation treatment regimen. During the telephone call, the patient will report the use of the Drinks Diary. |
The registered nurse (RN) will teach good mouth care and management of sore mouth or throat (mucositis) symptoms to the patient for self-management at home.
The RN will then call the patient twice every week to continue educating and coaching the patient about the mucositis self-management.
The patient will receive the Symptom Management (SxM) Toolkit which is a written educational guide known as the "Cancer Treatment Symptom Management Education Toolkit" geared to help the patient manage their symptoms of sore mouth and throat at home in order to prevent dehydration.
The patient will complete the Drinks Diary daily by recording the all oral fluid ingested and also record the number of times the bathroom is used.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of participants that completed calls
Time Frame: 6 weeks
|
Defined as the number of participants that completed 80% of the total 12 calls.
|
6 weeks
|
|
Duration of phone call
Time Frame: 6 weeks
|
Amount of time of the patient daily phone call (in minutes).
|
6 weeks
|
|
Percentage of patients using Intervention materials
Time Frame: 6 weeks
|
Percentage of the patients who reports using the interventions materials (SxM Toolkit and Drinks Diary).
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Attrition Rate
Time Frame: 6 weeks
|
Attrition rate will be comprised of those study participants who drop out of the study and be computed as a percent.
|
6 weeks
|
|
Study Completion Rate
Time Frame: 6 weeks
|
Length of time spent in the study will be expressed as a percent and it is expected that the participants will complete 75% of their planned chemoradiation treatments.
|
6 weeks
|
|
Participant Satisfaction
Time Frame: 6 weeks
|
Qualitative analysis of a customized Semi-Structured Interview
|
6 weeks
|
|
Change in severity of mucositis
Time Frame: 6 weeks
|
Mucositis severity will be measured daily by the Oral Mucositis Daily Questionnaire (OMDQ). A score of 0 equals no mucositis severity and high mucositis severity equals a score of 4 on question 2. |
6 weeks
|
|
Change in overall symptom severity
Time Frame: 10 weeks
|
The M.D. Anderson Symptom Inventory - Lung Cancer / Head & Neck Cancer(MDASI-LC; MDASI-HN) will be used to measure overall severity. The total MDASI-LC; HN score will be used in the analysis of overall symptom severity. Friedman's test is the test statistic that will be used to measure the effect of the intervention on overall symptom severity per cycle of chemoradiation treatment. |
10 weeks
|
|
Change in quality of life
Time Frame: 10 weeks
|
Health Related Quality of Life (HRQoL) will be measured by the Functional Assessment of Cancer Therapy - Lung and Head & Neck versions (FACT-L; FACT-H&N respectively ).
The FACT-L & FACT H&N are both a five domain, 36 item self-report instrument scored on a 5 point Likert scale (zero to 4) with a score range of 0-144; the higher the score = higher HRQoL.
|
10 weeks
|
|
Unscheduled Medical Visits
Time Frame: 6 weeks
|
Number of unplanned medical visits made by the patient to the Oncologist for intravenous fluid administration.
|
6 weeks
|
|
Influence of Nurse-Delivered Telephone Intervention on Self-Efficacy
Time Frame: 10 weeks
|
The adapted Chronic Disease Self-Efficacy Scale (CDSES) was developed by combining the subscales of Manage Disease in General Scale and the Symptoms Scale for a combined 10 item scale to measure the concept of perceived self-efficacy.
Each item is scored 0 to 8; with the higher combined sum score equating to a higher perceived self-efficacy in the participant.
|
10 weeks
|
|
Influence of Nurse-Delivered Telephone Intervention on Symptom Self-Management
Time Frame: 10 weeks
|
The Partners in Health Scale (PIHS) was designed to measure adherence to treatment, knowledge of disease, management of side effects and management of signs and symptoms over time.
The 12 item questionnaire scores each question among the domain categories on a 9 point scale from 0-8 and the higher sum score reflects a higher self-management in the participant.
|
10 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Raphael Yechieli, MD, University of Miami
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20180475
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Head and Neck Cancer
-
Robert FerrisAmgenCompletedHead and Neck Cancer | Cancer of Head and Neck | Head Cancer | Neck Cancer | Neoplasms, Head and Neck | Cancer of the Head and Neck | Cancer of Neck | Upper Aerodigestive Tract Neoplasms | Neck Neoplasms | Cancer of the Head | Cancer of the Neck | UADT Neoplasms | Cancer of Head | Head Neoplasms | Head, Neck Neoplasms | Neoplasms, Head and other conditionsUnited States
-
Assiut UniversityRecruitingHead and Neck Cancer | Head and Neck Neoplasms | Cancer of Head and Neck | Neoplasms, Head and Neck | Cancer of the Head and NeckEgypt
-
Mayo ClinicCompletedCancer Head Neck | Cancer Neck | Cancer, HeadUnited States
-
West China HospitalNot yet recruitingHead and Neck Cancer | Malignant Neoplasm | Advanced Head and Neck Carcinoma | Head &Amp; Neck Cancer
-
National Cancer Institute (NCI)TerminatedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerUnited States
-
Radboud University Medical CenterUnknown
-
Fondazione IRCCS Policlinico San Matteo di PaviaNestle Health Science; Akern SrlCompletedHead-neck CancerItaly
-
University of California, San FranciscoCompleted
-
Uppsala UniversityRegion Östergötland; Region Skane; Region Västerbotten; Swedish Cancer Society; S... and other collaboratorsNot yet recruitingHead and Neck Cancer | Head and Neck Cancer Squamous Cell CarcinomaSweden
-
Shenzhen SiBiono GeneTech Co.,LtdUnknownAdvanced Head and Neck CancerChina
Clinical Trials on Symptom Management Education and Nurse Coaching
-
University of UtahNational Cancer Institute (NCI); Emory University; Huntsman Cancer InstituteCompletedCancerUnited States
-
Izmir Katip Celebi UniversityCompletedInflammatory Bowel DiseasesTurkey (Türkiye)
-
US Department of Veterans AffairsDialysis Clinic, Inc.; DaVita Dialysis; Liberty Dialysis, LLCCompletedDepression | Pain | End Stage Renal Disease | Sexual Dysfunction, PhysiologicalUnited States
-
Celal Bayar UniversityCompleted
-
West China HospitalRecruiting
-
Karabuk UniversityActive, not recruitingHelp-Seeking Behavior | School Health | Focus | Symptom AwarenessTurkey (Türkiye)
-
Assistance Publique - Hôpitaux de ParisCompletedRheumatoid Arthritis (RA) | Spondyloarthritis (SpA)France
-
Johns Hopkins UniversityPatient-Centered Outcomes Research InstituteCompletedVenous Thrombosis (Disorder)United States
-
The Third Xiangya Hospital of Central South UniversityEnrolling by invitation